ArticleOncotarget2017
Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Green synthesis of Mn-doped iron oxide nanoparticles using sugarcane juice for magnetic hyperthermia applications.Scientific reports · 2025Article
- Functional role of P2X7 purinergic receptor in cancer and cancer-related pain.Purinergic signalling · 2025Review
- P2 purinergic receptors regulate the progression of colorectal cancer.Purinergic signalling · 2025Review
- Role and Therapeutic Potential of P2X7 Receptor in Lung Cancer Progression.Current medicinal chemistry · 2025Review
- "Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.Cancer communications (London, England) · 2024Review
- Purinergic P2X7R as a potential target for pancreatic cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Ion channel P2X7 receptor in the progression of cancer.Frontiers in oncology · 2023Review
- Amplifying cancer treatment: advances in tumor immunotherapy and nanoparticle-based hyperthermia.Frontiers in immunology · 2023Review
- Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study.Experimental and therapeutic medicine · 2022Article
- Hyperthermic intraperitoneal chemotherapy and colorectal cancer: From physiology to surgery.World journal of clinical cases · 2022Review
- Pannexin1 inhibits autophagy of cisplatin-resistant testicular cancer cells by mediating ATP release.Cell cycle (Georgetown, Tex.) · 2022Article
- Magnetic Hyperthermia Nanoarchitectonics via Iron Oxide Nanoparticles Stabilised by Oleic Acid: Anti-Tumour Efficiency and Safety Evaluation in Animals with Transplanted Carcinoma.International journal of molecular sciences · 2022Article
- Safety, feasibility, and application of intraperitoneal gas-based hyperthermia beyond 43°C in the treatment of peritoneal metastasis: AnFrontiers in oncology · 2022Article
- Article
- Effect of manganese doping on the hyperthermic profile of ferrite nanoparticles using response surface methodology.RSC advances · 2021Article
- Targeting ectonucleotidases to treat inflammation and halt cancer development in the gut.Biochemical pharmacology · 2021Review
- Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy.Purinergic signalling · 2021Review
- Review
- The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.Journal of cancer research and clinical oncology · 2020Review
- Gold Nanoparticles for Vectorization of Nucleic Acids for Cancer Therapeutics.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
Extracellular ATP (eATP) accumulation within the tumor microenvironment (TME) has the potential to activate purinergic signaling. The eATP evoked signaling effects bolster antitumor immune responses while exerting direct cytotoxicity on tumor cells and vascular endothelial cells, mediated at least in part through P2X7 receptors. Approaches to augment purinergic signaling in TME e.g. by ectonucleotidase CD39 blockade, and/or boosting P2X7 functional responses, might be used as immunomodulatory therapies in cancer treatment. In this study, we delineated the translatable strategy of hyperthermia to demonstrate impacts on P2X7 responsiveness to eATP. Hyperthermia (40°C) was noted to enhance eATP-mediated cytotoxicity on MCA38 colon cancer cells. Increased membrane fluidity induced by hyperthermia boosted P2X7 functionality, potentiating pore opening and modulating downstream AKT/PRAS40/mTOR signaling events. When combined with cisplatin or mitomycin C, hyperthermia and eATP together markedly potentiate cancer cell death. Our data indicate that clinically tolerable hyperthermia with modulated P2X7-purinergic signaling will boost efficacy of conventional cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.